Track topics on Twitter Track topics that are important to you
Results from the ZUMA-1 trial of axicabtagene ciloleucel (KTE-C19) in patients with chemorefractory aggressive non-Hodgkin lymphoma (NHL) were updated recently […]
The post Kite Pharma Updates Results of CAR-T cell therapy in Aggressive Non-Hodgkin Lymphoma appeared first on .NEXT ARTICLE
Hodgkin Lymphoma is a disorder caused by malignant proliferation of lymphocytes, which contain characteristic mirror-image nuclei (Reed-Sternburg cells). The resulting lymphadenopathy can be limited to a single lymph node region (Stage 1) or spread...